Except as provided in §§ 50.22 , 50.23 , and 50.24 , no investigator may involve a human being as a subject in research covered by these regulations unless the investigator has obtained the legally effective informed consent of the subject or the subject's legally authorized representative. An investigator shall seek such consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence. The information that is given to the subject or the representative shall be in language understandable to the subject or the representative. No informed consent, whether oral or written, may include any exculpatory language through which the subject or the representative is made to waive or appear to waive any of the subject's legal rights, or releases or appears to release the investigator, the sponsor, the institution, or its agents from liability for negligence.
21 CFR Part 50 · Protection of Human Subjects
§ 50.20 General requirements for informed consent
Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.
What FDA inspectors cite under § 50.20
Form FDA 483 observations citing this section, fiscal years 2009–2026 (Bioresearch Monitoring).
- Consent not obtained, exceptions do not apply 85
- Circumstances of obtaining consent 34
- Understandable language 28
- Exculpatory language, waiving of rights 8
Warning letters citing § 50.20
15 FDA warning letters since 2017 cite this section ; the most recent:
- Stephen J. Fallon, Ph.D. 27 Aug 2026
- Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd. 10 Jul 2026
- Sourav K. Mishra, M.D. / All India Institute of Medical Sciences 29 Apr 2026
- Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre 29 Apr 2026
- Adnan Dahdul, MD 12 Mar 2026
- Mark S. Dacey, M.D. 2 Feb 2026
- Shirish M. Gadgeel, M.D. 4 Sept 2025
- Mark J. Savant, M.D 26 Jun 2025
- Americo F. Padilla, M.D. 25 Mar 2025
- Namita A. Goyal, M.D. 10 Oct 2024
- Mobeen Mazhar, M.D. 31 May 2023
- Daniel Fred Goodman, M.D./Goodman Eye Center 14 Jul 2022
FDA guidance that cites § 50.20
- Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers 15 Apr 2026
- Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause draft 23 Feb 2026
- Enhancing Participation in Clinical Trials — Eligibility Criteria, Enrollment Practices, and Trial Designs: Guidance for Industry 15 Dec 2025
- Institutional Review Board (IRB) Written Procedures: Guidance for Institutions and IRBs 5 Feb 2025
- Institutional Review Boards Frequently Asked Questions: Guidance for Institutional Review Boards and Clinical Investigators 5 Feb 2025
- Considerations for Including Tissue Biopsies in Clinical Trials draft 7 Jan 2025
- Conducting Clinical Trials With Decentralized Elements 18 Sept 2024
- Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice: Draft Guidance for Industry draft 18 Sept 2024
- Key Information and Facilitating Understanding in Informed Consent Guidance for Sponsors, Investigators, and Institutional Review Boards draft 1 Mar 2024
- Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment : Guidance for Industry 22 Feb 2024
- CVM GFI #282 Informed Consent Forms for Studies that Enroll Client-Owned Companion Animals draft 15 Sept 2023
- Informed Consent: Guidance for IRBs, Clinical Investigators, and Sponsors 15 Aug 2023
- Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry: Guidance for Industry 1 Mar 2022
- IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations: Draft Guidance for Industry draft 8 Dec 2021
- IND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators draft 4 Jan 2021
and 16 more.
Amendment history
Federal Register documents that created or amended this section.
- 46 FR 8951 27 Jan 1981
- 64 FR 10942 8 Mar 1999
- 88 FR 88248 21 Dec 2023